Stocks TelegraphStocks Telegraph
Stock Ideas

MREO Financial Statements and Analysis

NASDAQ : MREO

Mereo BioPharma Group

$0.25
-0.0135-5.20%
At Close 4:00 PM
50
BESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q3
revenue00500.00K00
cost of revenue01.00K132.00K00
gross profit0-1.00K368.00K00
gross profit ratio000.73600
research and development expenses4.747M3.824M5.373M3.93M3.17M
general and administrative expenses4.019M6.045M5.494M7.272M6.203M
selling and marketing expenses00000
selling general and administrative expenses4.019M6.045M5.494M7.272M6.203M
other expenses0145.00K000
operating expenses8.766M10.014M10.867M11.202M9.373M
cost and expenses010.015M10.999M11.202M9.373M
interest income327.00K500.973K589.00K659.00K983.00K
interest expense-20.00K27.831K24.00K180.00K353.00K
depreciation and amortization054.00K298.00K270.00K282.00K
ebitda-8.766M-9.815M-14.294M-12.437M-14.366M
ebitda ratio00-28.58800
operating income-8.766M-10.015M-10.499M-11.202M-9.373M
operating income ratio00-20.99800
total other income expenses net2.047M2.991M-4.117M-1.685M-5.628M
income before tax-6.719M-7.024M-14.616M-12.887M-15.001M
income before tax ratio00-29.23200
income tax expense00000
net income-6.719M-7.024M-14.616M-12.887M-15.001M
net income ratio00-29.23200
eps-0.05-0.05-0.093-0.082-100.02
eps diluted-0.05-0.05-0.093-0.082-100.02
weighted average shs out160.361M159.989M159.887M156.856M770.147M
weighted average shs out dil160.361M159.989M159.887M156.856M770.147M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q3
cash and cash equivalents36.223M48.698M56.125M62.483M80.522M
short term investments00000
cash and short term investments36.223M48.698M56.125M62.483M80.522M
net receivables003.747M2.398M2.843M
inventory00000
other current assets3.811M3.709M1.549M2.018M3.358M
total current assets40.034M52.407M61.421M66.899M86.723M
property plant equipment net199.00K552.00K740.00K869.00K1.224M
goodwill00000
intangible assets381.00K643.00K470.00K554.00K799.00K
goodwill and intangible assets381.00K643.00K470.00K554.00K799.00K
long term investments00000
tax assets00000
other non current assets00000
total non current assets580.00K1.195M1.21M1.423M2.023M
other assets00000
total assets40.614M53.602M62.631M68.322M88.746M
account payables3.226M879.00K1.138M2.924M1.748M
short term debt0397.00K601.00K747.00K736.00K
tax payables00485.00K370.00K2.276M
deferred revenue00000
other current liabilities2.951M4.74M5.333M3.456M9.448M
total current liabilities6.177M6.016M7.557M7.497M14.208M
long term debt0000394.00K
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities383.00K988.00K897.00K744.00K1.608M
total non current liabilities383.00K988.00K897.00K744.00K2.002M
other liabilities00000
capital lease obligations0397.00K601.00K747.00K1.13M
total liabilities6.56M7.004M8.454M8.241M16.21M
preferred stock00000
common stock3.145M3.134M3.132M3.132M3.051M
retained earnings-507.538M-493.667M-486.643M-472.027M-455.837M
accumulated other comprehensive income loss-12.571M-10.91M-8.643M-15.29M-11.104M
other total stockholders equity551.018M548.041M546.331M544.266M536.426M
total stockholders equity34.054M46.598M54.177M60.081M72.536M
total equity34.054M46.598M54.177M60.081M72.536M
total liabilities and stockholders equity40.614M53.602M62.631M68.322M88.746M
minority interest00000
total investments00000
total debt0397.00K601.00K747.00K1.13M
net debt-36.223M-48.301M-55.524M-61.736M-79.392M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q2
deferred income tax00000
stock based compensation1.605M02.065M2.278M2.088M
change in working capital0636.00K-843.00K-514.00K1.66M
accounts receivables00-744.00K952.00K-370.537K
inventory00000
accounts payables1.957M0-1.951M362.00K241.187K
other working capital0636.00K1.852M-1.828M1.79M
other non cash items631.00K-910.00K5.445M2.524M3.082M
net cash provided by operating activities-4.312M-7.309M-7.651M-8.329M-7.914M
investments in property plant and equipment000-20.00K381.00
acquisitions net00000
purchases of investments00000
sales maturities of investments00000
other investing activites-300.00K300.00K0-300.00K1.00K
net cash used for investing activites-300.00K300.00K0-320.00K381.00
debt repayment0000-219.068K
common stock issued000047.015M
common stock repurchased00000
dividends paid00000
other financing activites00-134.00K422.00K46.781M
net cash used provided by financing activities00-134.00K422.00K46.796M
effect of forex changes on cash0-418.00K1.427M908.00K-107.00K
net change in cash-4.612M-7.427M-6.358M-7.319M38.771M
cash at end of period048.698M56.125M62.483M87.431M
cash at beginning of period056.125M62.483M69.802M48.66M
operating cashflow-4.312M-7.309M-7.651M-8.329M-7.914M
capital expenditure000-320.00K381.00
free cash flow-4.312M-7.309M-7.651M-8.649M-7.913M
Graph

Frequently Asked Questions

How did Mereo BioPharma Group plc do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, MREO generated $0.00 in revenue last quarter, while its costs came in at $0.00.
Last quarter, how much Gross Profit did Mereo BioPharma Group plc report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Mereo BioPharma Group plc reported a $0.00 Gross Profit for the quarter ended Mar 31, 2026.
Have MREO's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. MREO incurred $8.77M worth of Operating Expenses, while it generated -$8.77M worth of Operating Income.
How much Net Income has MREO posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Mereo BioPharma Group plc, the company generated -$6.72M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Mereo BioPharma Group plc have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Mereo BioPharma Group plc as of the end of the last quarter was $36.22M.
What are MREO's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, MREO had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did Mereo BioPharma Group plc stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of MREO were $40.03M, while the Total Assets stand at $40.61M.
As of the last quarter, how much Total Debt did Mereo BioPharma Group plc have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of MREO's debt was $0.00 at the end of the last quarter.
What were MREO's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, MREO reported total liabilities of $6.56M.
How much did MREO's Working Capital change over the last quarter?
Working Capital Change for MREO was $0.00 over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
MREO generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. MREO generated -$4.31M of Cash from Operating Activities during its recently reported quarter.
What was MREO's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. MREO reported a -$4.61M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph